Citadel Advisors
TBPH icon

Citadel Advisors’s Theravance Biopharma TBPH Stock Holding History

Citadel Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Sell
86,091
-149,609
-63% -$2.65M ﹤0.01% 6880
2025
Q4 		$4.41M Buy
235,700
+184,833
+363% +$3.07M ﹤0.01% 4472
2025
Q3 		$743K Sell
50,867
-434,464
-90% -$5.49M ﹤0.01% 8200
2025
Q2 		$5.35M Buy
485,331
+46,622
+11% +$453K ﹤0.01% 3983
2025
Q1 		$3.92M Buy
438,709
+124,087
+39% +$1.15M ﹤0.01% 4292
2024
Q4 		$2.96M Buy
314,622
+80,066
+34% +$729K ﹤0.01% 4856
2024
Q3 		$1.89M Sell
234,556
-9,458
-4% -$81.9K ﹤0.01% 5647
2024
Q2 		$2.07M Buy
244,014
+128,206
+111% +$1.16M ﹤0.01% 5234
2024
Q1 		$1.04M Sell
115,808
-34,314
-23% -$318K ﹤0.01% 6834
2023
Q4 		$1.69M Buy
150,122
+113,403
+309% +$1.14M ﹤0.01% 5675
2023
Q3 		$317K Sell
36,719
-44,298
-55% -$428K ﹤0.01% 9066
2023
Q2 		$839K Buy
81,017
+15,441
+24% +$171K ﹤0.01% 6823
2023
Q1 		$712K Sell
65,576
-18,770
-22% -$198K ﹤0.01% 7528
2022
Q4 		$946K Sell
84,346
-166,101
-66% -$1.75M ﹤0.01% 6926
2022
Q3 		$2.54M Buy
250,447
+234,539
+1,474% +$2.2M ﹤0.01% 5132
2022
Q2 		$144K Sell
15,908
-635
-4% -$5.85K ﹤0.01% 11024
2022
Q1 		$158K Buy
16,543
+5,897
+55% +$57.8K ﹤0.01% 11796
2021
Q4 		$117K Buy
+10,646
New +$92.8K ﹤0.01% 12554
2020
Q4 		– Sell
-148,752
Closed -$2.2M – 11510
2020
Q3 		$2.2M Sell
148,752
-22,229
-13% -$416K ﹤0.01% 4547
2020
Q2 		$3.59M Buy
170,981
+150,527
+736% +$3.87M ﹤0.01% 3564
2020
Q1 		$473K Sell
20,454
-948
-4% -$23.7K ﹤0.01% 6542
2019
Q4 		$554K Buy
+21,402
New +$416K ﹤0.01% 6653
2019
Q3 		– Sell
-17,403
Closed -$284K – 9743
2019
Q2 		$284K Sell
17,403
-67,338
-79% -$1.36M ﹤0.01% 7666
2019
Q1 		$1.92M Buy
84,741
+54,460
+180% +$1.38M ﹤0.01% 4534
2018
Q4 		$775K Buy
30,281
+9,214
+44% +$249K ﹤0.01% 5710
2018
Q3 		$688K Sell
21,067
-11,715
-36% -$319K ﹤0.01% 6189
2018
Q2 		$743K Buy
+32,782
New +$778K ﹤0.01% 5725
2017
Q2 		– Sell
-85,100
Closed -$3.13M – 8050
2017
Q1 		$3.13M Buy
+85,100
New +$2.72M ﹤0.01% 2534
2016
Q1 		– Sell
-13,537
Closed -$222K – 7917
2015
Q4 		$222K Buy
+13,537
New +$215K ﹤0.01% 5671
2015
Q2 		– Sell
-38,111
Closed -$591K – 9092
2015
Q1 		$662K Sell
38,111
-9,981
-21% -$183K ﹤0.01% 4506
2014
Q4 		$717K Buy
48,092
+34,089
+243% +$594K ﹤0.01% 4213
2014
Q3 		$323K Sell
14,003
-25,696
-65% -$746K ﹤0.01% 5175
2014
Q2 		$1.27M Buy
+39,699
New +$1.2M ﹤0.01% 3201

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's TBPH Position: Q1 2026 in Review

Citadel Advisors reduced its Theravance Biopharma (TBPH) stake by 63% in Q1 2026, selling an estimated $2.65M and leaving 86,091 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #6880.

Citadel Advisors first reported a position in TBPH in Q2 2014 and has held it in 33 quarters since. The position peaked at $5.35M in Q2 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Citadel Advisors held 86,091 shares of Theravance Biopharma worth $1.4M as of Q1 2026.
  • Citadel Advisors sold 149,609 Theravance Biopharma shares in Q1 2026, an estimated $2.65M.
  • Theravance Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6880 holding.
  • Citadel Advisors first reported a position in Theravance Biopharma in Q2 2014 and has held it in 33 quarters since.
  • Citadel Advisors's Theravance Biopharma position peaked at $5.35M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.